ACR 2021

New treatment alternative in GCA: promising secukinumab…

No need for methotrexate in ustekinumab treatment in…

IL-17 pathway important for pain in PsA

ARIAA: prevention study or very early treatment of RA?

Dear Doctor: JAKi risk factors and safety profile - is…

axPsA is axSpA is not...!?

Cycling JAKi compared to switching to biologic DMARD in…

Tofacitinib is associated with a slightly increased…

Cardiovascular disease in RA

Discordance between patients and physicians in RA

Abatacept may reduce subclinical inflammation in RA-at…

Statins reduce cardiovascular risk and​ mortality -…

Long awaited - MACE data from ORAL surveillance

We need predictors of response for RA treatment

Nausea & alopecia with MTX in RA

Quels marqueurs de réponse aux traitements dans la…

Abatacept reduce la inflamación subclínica en pacientes…

Tofacitinid se asocia con un ligero incremento del…

Désaccords patient/Médecin : se comprendre pour plus…

Las estatinas reducen el riesgo cardiovascular y la…

Quels effets indésirables peuvent être associés à la…

Lange erwartet - MACE-Daten zur ORAL Surveillance

Association of C-reactive protein and non-steroidal…

No need for MTX in ustekinumab-treated patients

Osteoporosis in PsA

Joint effusions and enthesitis after physical exertion

PET/CT in diagnosis for PsA

Guselkumab: the better ustekinumab?!

Axial PsA MRI data

Tildrakizumab in PsA

Guselkumab in axial symptoms

Upadacitinib in PsA

Prediction of psoriatic arthritis in patients with…

Pain differs: Superior effect of IL-17-inhibition vs.…

Secukinumab vs TNF-α blockers in enthesitis

Anemia is an issue in PsA - proper treatment possible!

Osteoporose bei PsA

Associazione di livelli di PCR e uso di FANS con gli…

Kein Hinweis auf Vorteil einer MTX-Kombi zu Ustekinumab

Guselkumab bei axialer Symptomatik

Anämie bei PsA ist ein Thema - effektive Therapie…

Guselkumab: das bessere Ustekinumab?!

Studio di confronto tra i vari indici compositi per la…

PET-CT zur Quantifizierung der Entzündung

Upadacitinib bei PsA

Secukinumab vs TNF-α Blocker bei Enthesitis

Schmerz ist nicht gleich Schmerz: Unterschied von…

Datos de RM en APs axial

Gelenkergüsse und Enthesitis nach körperlicher…

Previsione di sviluppo di artrite psoriasica in…

Dose tapering of TNF inhibitors in axSpA

JAK inhibitors - new kids on the block

Axial PsA MRI data

Inhibidores JAK: nuevas dianas en EspAax

l’auto-monitoraggio di malattia è fattibile nella…

Datos de RM en APs axial

Not yet a new standard: belimumab + rituximab

JAK-Inhibitor Baricitinib in Phase II erfolgreich

PET as a predictor of vascular damage in large-vessel…

Baricitinib in relapsing giant cell arteritis

Secukinumab in giant cell arteritis

Il ruolo della PET nel predire il danno vascolare nelle…

Baricitinib nell'arterite a cellule giganti recidivante

Secukinumab nell'arterite a cellule giganti

Breakthrough infections after SARS-CoV2-vaccination -…

Vaccination against Delta variant worse in patients…

Analysis of COVID-19 infection among vaccinated…

Anticytokine antibodies causing severe microbacterial…

Booster with which one if there is no seroconversion?

Breakthrough infections after SARS-CoV2-vaccination -…

Impact of COVID-19 on patients with rheumatic diseases

Immune responses to COVID-19 vaccines

TNF blockers reduce the antibody response to RNA…

Durchbruchsinfektionen nach SARS-CoV2-Impfung -…

Durchbruchsinfektionen nach SARS-CoV2-Impfung -…

Schlechtere Neutralisation der Delta-Variante unter…

Immunresponser til COVID-19 vaksiner

Womit boostern bei fehlender Serokonversion?

Skin findings in patients of color with rheumatic…

Pearls and myths in rheumatology

New exciting data - dietary supplements with vitamin D…

Therapeutic drug monitoring - a randomized controlled…

PROs from a real-world study on etanercept biosimilar -…

Neue spannende Daten - Nahrungsergänzung mit Vitamin D…